Oxycodone controlled-release - Intellipharmaceutics

Drug Profile

Oxycodone controlled-release - Intellipharmaceutics

Alternative Names: Abuse deterrent oxycodone hydrochloride extended release tablets - Intellipharmaceutics; Abuse-resistant oxycodone - Intellipharmaceutics; Oxycodone CR - Intellipharmaceutics; Rexista oxycodone

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Intellipharmaceutics International
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 10 Apr 2017 Purdue Pharmaceuticals files patent infringement against Intellipharmaceutics with respect to NDA filing in USA
  • 24 Feb 2017 The US FDA issues a stay of 30 months from granting final approval to oxycodone hydrochloride extended release (Rexista™) for Pain, following patent infringement proceedings
  • 06 Feb 2017 The US FDA sets PDUFA date of 25 September 2017 for NDA review for Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top